Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions

The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has shown dramatic effects in patients with non‐small cell lung cancer (NSCLC) harboring ROS1 fusion genes. However, patients inevitably develop resistance to this agent. Therefore, a new treatment strategy is required for lung tumors with ROS1 fus...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Sci
Main Authors: Kato, Yuka, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tomida, Shuta, Makimoto, Go, Watanabe, Hiromi, Kudo, Kenichiro, Matsumoto, Shingo, Umemura, Shigeki, Goto, Koichi, Ichihara, Eiki, Ninomiya, Takashi, Kubo, Toshio, Sato, Akiko, Hotta, Katsuyuki, Tabata, Masahiro, Toyooka, Shinichi, Maeda, Yoshinobu, Kiura, Katsuyuki
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2018
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6172052/
https://ncbi.nlm.nih.gov/pubmed/30053332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13752
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker